Source comparison
Growth Hormone Secretagogue Mechanisms: GHRH Versus Ghrelin Pathways
Growth hormone secretagogues don't increase GH through a single universal pathway—they split into two mechanistically distinct classes based on receptor target. GHRH (growth hormone-releasing hormone) analogs bind GHRH receptors on somatotroph cells in the ant
This comparison does not assign a generated winner or score.
- Growth hormone secretagogues don't increase GH through a single universal pathway—they split into two mechanistically distinct classes based on receptor target. GHRH (growth hormone-releasing hormone) analogs bind GHRH receptors on somatotroph cells in the anterior pituitary, triggering cAMP-mediated signaling that extends the duration of endogenous GH pulses without necessarily increasing amplitude. This is why compounds like CJC-1295 and sermorelin produce smooth, prolonged elevations that mirror natural nocturnal secretion patterns. The GHRH pathway respects the body's feedback inhibition through somatostatin—when somatostatin is elevated, GHRH analogs are blunted, which is why timing administration around natural GH troughs (late afternoon or before sleep) matters significantly in research models.
- Ghrelin receptor agonists—often called growth hormone-releasing peptides (GHRPs)—work through an entirely different mechanism. Compounds like ipamorelin, GHRP-2, GHRP-6, and hexarelin bind the GHS-R1a receptor (ghrelin receptor), which triggers calcium influx and activates protein kinase C pathways independent of GHRH. This produces sharp, high-amplitude GH pulses that can override somatostatin inhibition to a degree—making ghrelin mimetics less timing-dependent but more prone to desensitization with chronic administration. The GHS-R1a receptor is expressed not only in the pituitary but also in the hypothalamus, heart, adipose tissue, and gastrointestinal tract, which explains why ghrelin-based secretagogues often produce secondary effects on appetite (particularly GHRP-6), gastric motility, and cardiovascular parameters.
- MK-677 (ibutamoren) occupies a unique position—it's a non-peptide ghrelin mimetic with oral bioavailability and a half-life exceeding 24 hours, producing sustained GH and IGF-1 elevation rather than pulsatile spikes. A 1997 study published in the Journal of Clinical Endocrinology & Metabolism demonstrated that 25mg daily MK-677 increased mean 24-hour GH concentration by 97% and IGF-1 levels by 88% in healthy adults over two months. The tradeoff is that sustained GH elevation diverges from physiological pulsatility, which some research models require—pulsatile GH release has distinct metabolic and anabolic signaling effects compared to continuous elevation.
- Real Peptides offers research-grade formulations of both pathway classes, including CJC-1295 with and without DAC, ipamorelin, GHRP-2, GHRP-6, hexarelin, sermorelin, tesamorelin, and MK-677, each synthesized through exact amino-acid sequencing to guarantee batch consistency. Understanding which receptor pathway your protocol requires determines which compound class to select.